share_log

Senti Biosciences | 4: Statement of changes in beneficial ownership of securities-Director Collins James J.

Senti Biosciences | 4: Statement of changes in beneficial ownership of securities-Director Collins James J.

Senti Biosciences | 4：持股變動聲明-董事 Collins James J.
美股SEC公告 ·  07/13 04:18
牛牛AI助理已提取核心訊息
James J. Collins, associated with Senti Biosciences, Inc. (SNTI.US), was involved in a transaction with the company's stock on July 10, 2024. The specific details regarding the nature of the transaction, such as the number of shares traded, the transaction price, and the resulting ownership stake, have not been disclosed. This information is crucial for investors to understand the implications of insider actions on their investment decisions.
James J. Collins, associated with Senti Biosciences, Inc. (SNTI.US), was involved in a transaction with the company's stock on July 10, 2024. The specific details regarding the nature of the transaction, such as the number of shares traded, the transaction price, and the resulting ownership stake, have not been disclosed. This information is crucial for investors to understand the implications of insider actions on their investment decisions.
2024年7月10日，Senti Biosciences, Inc. (SNTI.US) 的 James J. Collins 參與了公司股票的交易。關於交易性質的具體細節，例如交易的股票數量、交易價格和產生的所有權份額尚未公開披露。這些信息對投資者理解內幕交易行爲對其投資決策的影響至關重要。
2024年7月10日，Senti Biosciences, Inc. (SNTI.US) 的 James J. Collins 參與了公司股票的交易。關於交易性質的具體細節，例如交易的股票數量、交易價格和產生的所有權份額尚未公開披露。這些信息對投資者理解內幕交易行爲對其投資決策的影響至關重要。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。